Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101

SBIJI Innovation
Sep 29, 2020
1 min read

Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for the treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma with Notch Activating Mutations at ESMO 2020

– Interim data showed meaningful clinical activity of AL101 4mg monotherapy with deep responses and 68% disease control rate

Read More

Recent Posts

See All

Orasis Pharmaceuticals Announces Licensing Agreement with Optus Pharmaceuticals for Commercialization of Qlosi™

October 16, 2024 Exclusive Agreement Includes $18 Million in Milestone Payments to Orasis, Together with a Double-Digit Royalty on Sales...

Secret Double Octopus Secures Strategic Investment from SBI Holdings to Propel Global Expansion of Workforce Passwordless Authentication

October 29, 2024 MENLO PARK, Calif.–( BUSINESS WIRE )–Secret Double Octopus, the market leader in workforce passwordless authentication,...

ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease

ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002...

Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101

Recent Posts

Comments

A Member firm of SBI Group, Japan

© 2020 SBI JI Innovation Advisory Ltd. All rights reserved